Literature DB >> 7721402

Early predictors of 15-year end-stage renal disease in hypertensive patients.

H M Perry1, J P Miller, J R Fornoff, J D Baty, M P Sambhi, G Rutan, D W Moskowitz, S E Carmody.   

Abstract

There has been a continuing increase in the incidence of end-stage renal disease (ESRD) in the United States, including the fraction that has been attributed to hypertension. This study was done to seek relationships between ESRD and pretreatment clinical data and between ESRD and early treated blood pressure data in a population of hypertensive veterans. We identified a total of 5730 black and 6182 nonblack male veterans as hypertensive from 1974 through 1976 in 32 Veterans Administration Hypertension Screening and Treatment Program clinics. Their mean age was 52.5 +/- 10.2 years, and their mean pretreatment blood pressure was 154.3 +/- 19.0/100.8 +/- 9.8 mm Hg. During a minimum of 13.9 years of follow-up, 5337 (44.8%) of these patients died and 245 developed ESRD. For 1055 of these subjects, pretreatment systolic blood pressure (SBP) was greater than 180 mm Hg; 901 were diabetic; 1471 had a history of urinary tract problems; and 2358 of the 9644 who were treated had an early fall in SBP of more than 20 mm Hg. We used proportional hazards modeling to fit multivariate survival models to determine the effect of the available pretreatment data and early treated blood pressure levels on ESRD. This model demonstrated the independent increased risk of ESRD associated with being black or diabetic (risk ratio, 2.2 or 1.8), having a history of urinary tract problems (risk ratio, 2.2), or having high pretreatment SBP (for SBP 165 to 180 mm Hg, risk ratio was 2.8; for SBP > 180 mm Hg, risk ratio was 7.6).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7721402     DOI: 10.1161/01.hyp.25.4.587

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  62 in total

Review 1.  The need to lower systolic blood pressure.

Authors:  S Shrivastava; M S Kochar
Journal:  Curr Hypertens Rep       Date:  2000-10       Impact factor: 5.369

Review 2.  Is there a preferred antihypertensive therapy for isolated systolic hypertension and reduced arterial compliance?

Authors:  S S Franklin
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

Review 3.  Epidemiology of hypertensive kidney disease.

Authors:  Suneel Udani; Ivana Lazich; George L Bakris
Journal:  Nat Rev Nephrol       Date:  2010-11-16       Impact factor: 28.314

Review 4.  Renal protection in hypertensive patients: selection of antihypertensive therapy.

Authors:  René R Wenzel
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Epidemiology of obesity, the metabolic syndrome, and chronic kidney disease.

Authors:  Rikki M Tanner; Todd M Brown; Paul Muntner
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

6.  Risk factors for end-stage renal disease: 25-year follow-up.

Authors:  Chi-yuan Hsu; Carlos Iribarren; Charles E McCulloch; Jeanne Darbinian; Alan S Go
Journal:  Arch Intern Med       Date:  2009-02-23

7.  Association of body mass index with outcomes in patients with CKD.

Authors:  Jun Ling Lu; Kamyar Kalantar-Zadeh; Jennie Z Ma; L Darryl Quarles; Csaba P Kovesdy
Journal:  J Am Soc Nephrol       Date:  2014-03-20       Impact factor: 10.121

Review 8.  Blood pressure level and kidney disease progression: do we really need to go to 130/80 mm Hg?

Authors:  Bassam G Abu Jawdeh; Mahboob Rahman
Journal:  Curr Hypertens Rep       Date:  2009-10       Impact factor: 5.369

9.  A Concept-Wide Association Study of Clinical Notes to Discover New Predictors of Kidney Failure.

Authors:  Karandeep Singh; Rebecca A Betensky; Adam Wright; Gary C Curhan; David W Bates; Sushrut S Waikar
Journal:  Clin J Am Soc Nephrol       Date:  2016-10-10       Impact factor: 8.237

10.  End-stage renal disease in young black males in a black-white population: longitudinal analysis of the Bogalusa Heart Study.

Authors:  Paul Muntner; Asghar Arshad; Stephen A Morse; Dharmendrakumar A Patel; Pronabesh D Manapatra; Efrain Reisin; Erwin A Aguilar; Wei Chen; Sathanur Srinivasan; Gerald S Berenson
Journal:  BMC Nephrol       Date:  2009-12-02       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.